Andrew Schneider, DPM said: January 22, 2008 10:26 am PST
I've been using MicroVas for just over three years now. There definitely is therapeutic benefits. To date I've used it for diabetic and non-diabetic neuropathy, diabetic wounds, Morton's neuroma, and plantar fasciitis with varied results. By far, the most dramatic results have been with diabetic neuropathy and wounds. Because both have a microvascular etiology, this therapy is particularly suited for these uses, since it stimulates microvascular angiogenesis. In a two year follow-up with patients treated for diabetic neuropathy, there has been no return in symptoms except where the patient's diabetes has become uncontrolled and neuropathic symptoms return. I have stopped using MicroVas for non-diabetic neuropathy as I have not seen the same benefits. As for Morton's neuroma and plantar fasciitis, I use the therapy rarely and usually at the patient's request as a last resort to avoid surgery or ESWT. Results have been mixed.
The downside of the therapy is that it is an in-office 45 minute treatment
that keeps a room occupied for about an hour. If you are short on treatment rooms, you may want to consider that issue. Also, I have found that maximum benefit occurs with treatment 3 times a week, which some patients can't commit to.
The therapy is profitable. The payment can be easily covered by 1 patient per month (treated 3 times a week, which has been my standard protocol). There have just been double blind studies completed and the company hopes for a dedicated CPT code instead of the PT codes it currently uses. They
think that this will increase reimbursement, but it can backfire like it did for Anodyne and lower reimbursement too. Overall, I consider MicroVas a fantastic adjunct to my wound care practice as well as much needed relief for patients with diabetic neuropathy.
Andrew Schneider, DPM
Houston, TX